Your browser doesn't support javascript.
loading
Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine.
Carlsson, Leif; Clarke, Jonathan C; Yen, Christopher; Gregoire, Francine; Albery, Tamsin; Billger, Martin; Egnell, Ann-Charlotte; Gan, Li-Ming; Jennbacken, Karin; Johansson, Edvin; Linhardt, Gunilla; Martinsson, Sofia; Sadiq, Muhammad Waqas; Witman, Nevin; Wang, Qing-Dong; Chen, Chien-Hsi; Wang, Yu-Ping; Lin, Susan; Ticho, Barry; Hsieh, Patrick C H; Chien, Kenneth R; Fritsche-Danielson, Regina.
Afiliación
  • Carlsson L; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Clarke JC; Integrated Cardiometabolic Center, Karolinska Institute, Huddinge 141 52, Sweden.
  • Yen C; Department of Cell and Molecular Biology and Medicine, Karolinska Institute, Stockholm 171 77, Sweden.
  • Gregoire F; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Albery T; Moderna Therapeutics, Cambridge, MA, USA.
  • Billger M; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Egnell AC; Drug Safety and Metabolism, Regulatory Safety, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Gan LM; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Jennbacken K; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Johansson E; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Linhardt G; Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Martinsson S; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Sadiq MW; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Witman N; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Wang QD; Department of Cell and Molecular Biology and Medicine, Karolinska Institute, Stockholm 171 77, Sweden.
  • Chen CH; Innovative Medicines and Early Development Biotech Unit, Cardiovascular, Renal and Metabolic Diseases, AstraZeneca, Mölndal 431 83, Sweden.
  • Wang YP; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Lin S; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Ticho B; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Hsieh PCH; Moderna Therapeutics, Cambridge, MA, USA.
  • Chien KR; Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan.
  • Fritsche-Danielson R; Institute of Medical Genomics and Proteomics, Institute of Clinical Medicine and Cardiovascular Surgery Division, National Taiwan University and Hospital, Taipei 100, Taiwan.
Mol Ther Methods Clin Dev ; 9: 330-346, 2018 Jun 15.
Article en En | MEDLINE | ID: mdl-30038937
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Año: 2018 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos